The Use of Continuous Subcutaneous Octreotide Infusion in Brittle Type 1 Diabetic Patients

F. Bello; J. M. Falko; T. M. O'Dorisio; K. Osei

doi:10.1111/j.1464-5491.1991.tb01615.x

The Use of Continuous Subcutaneous Octreotide Infusion in Brittle Type 1 Diabetic Patients

F. Bello
, J. M. Falko
, T. M. O'Dorisio
, K. Osei

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Two Type 1 diabetic patients with brittle diabetes were successfully treated using continuous SC octreotide (Sandostatin) infusion (200 μg 24‐h⁻¹) for 6 months and 12 months. When the analogue was discontinued, rapid deterioration in glucose control and ketonuria recurred in one patient and diabetic ketoacidosis in the other. These were corrected after reinstitution of the analogue. 1991 Diabetes UK

Original language	English
Pages (from-to)	385-387
Number of pages	3
Journal	Diabetic Medicine
Volume	8
Issue number	4
DOIs	https://doi.org/10.1111/j.1464-5491.1991.tb01615.x
State	Published - May 1991

Keywords

Brittle diabetes
Octreotide

Access to Document

10.1111/j.1464-5491.1991.tb01615.x

Cite this

@article{5474b0fff7d747429f86f16ba1bf52cb,

title = "The Use of Continuous Subcutaneous Octreotide Infusion in Brittle Type 1 Diabetic Patients",

abstract = "Two Type 1 diabetic patients with brittle diabetes were successfully treated using continuous SC octreotide (Sandostatin) infusion (200 μg 24‐h−1) for 6 months and 12 months. When the analogue was discontinued, rapid deterioration in glucose control and ketonuria recurred in one patient and diabetic ketoacidosis in the other. These were corrected after reinstitution of the analogue. 1991 Diabetes UK",

keywords = "Brittle diabetes, Octreotide",

author = "F. Bello and Falko, \{J. M.\} and O'Dorisio, \{T. M.\} and K. Osei",

year = "1991",

month = may,

doi = "10.1111/j.1464-5491.1991.tb01615.x",

language = "English",

volume = "8",

pages = "385--387",

journal = "Diabetic Medicine",

issn = "0742-3071",

number = "4",

}

TY - JOUR

T1 - The Use of Continuous Subcutaneous Octreotide Infusion in Brittle Type 1 Diabetic Patients

AU - Bello, F.

AU - Falko, J. M.

AU - O'Dorisio, T. M.

AU - Osei, K.

PY - 1991/5

Y1 - 1991/5

N2 - Two Type 1 diabetic patients with brittle diabetes were successfully treated using continuous SC octreotide (Sandostatin) infusion (200 μg 24‐h−1) for 6 months and 12 months. When the analogue was discontinued, rapid deterioration in glucose control and ketonuria recurred in one patient and diabetic ketoacidosis in the other. These were corrected after reinstitution of the analogue. 1991 Diabetes UK

AB - Two Type 1 diabetic patients with brittle diabetes were successfully treated using continuous SC octreotide (Sandostatin) infusion (200 μg 24‐h−1) for 6 months and 12 months. When the analogue was discontinued, rapid deterioration in glucose control and ketonuria recurred in one patient and diabetic ketoacidosis in the other. These were corrected after reinstitution of the analogue. 1991 Diabetes UK

KW - Brittle diabetes

KW - Octreotide

UR - https://www.scopus.com/pages/publications/0025905776

U2 - 10.1111/j.1464-5491.1991.tb01615.x

DO - 10.1111/j.1464-5491.1991.tb01615.x

M3 - Article

C2 - 1830262

AN - SCOPUS:0025905776

SN - 0742-3071

VL - 8

SP - 385

EP - 387

JO - Diabetic Medicine

JF - Diabetic Medicine

IS - 4

ER -

The Use of Continuous Subcutaneous Octreotide Infusion in Brittle Type 1 Diabetic Patients

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this